Table 3.

Proposed European Organization for Research and Treatment of Cancer criteria for assessment of response by FDG-PET

Progressive metabolic disease
    Increase of SUV >25%
    Visible increase of FDG uptake (>20% of longest dimension)
    Appearance of new focus
Stable metabolic disease
    Increase of SUV <25% or decrease <15%
    No visible increase of the extent of FDG uptake
Partial metabolic response
    Reduction of a minimum of 15-25% of SUV after one treatment cycle; >25% after more than one treatment cycle
Complete metabolic response
    Complete resolution of FDG uptake